Highlights
- Market Cap
- $7.95M
- Enterprise Value
- $3.71B
- EPS (TTM)
- -$952.98
- Total Revenue (TTM)
- $8.67K
- Gross Profit (TTM)
- -$58.68K
- EBITDA (TTM)
- -$1.93B
- Year Range
- $2.01 - $6.47
- Target Price
- $3.00
- ROA (TTM)
- -26.36%
- ROE (TTM)
- -75.10%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Heart Test Laboratories Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Heart Test Laboratories Inc. Common Stock (HSCS) has returned -18.64% so far this year and -10.85% over the past 12 months.
Heart Test Laboratories Inc. Common Stock
- 1D
- 11.24%
- 1M
- -9.76%
- YTD
- -18.64%
- 6M
- -27.76%
- 1Y
- -10.85%
- 3Y*
- -70.58%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jun 15, 2022, HSCS's average daily return is -0.01%, while the average monthly return is -4.18%.
Historically, 33% of months were positive and 67% were negative. The best month was Jan 2023 with a return of +154.8%, while the worst month was Nov 2022 at -50.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 15 months.
On a daily basis, HSCS closed higher 42% of trading days. The best single day was Jan 30, 2023 with a return of +170.1%, while the worst single day was May 17, 2024 at -38.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.53% | -13.75% | -9.76% | -18.64% | |||||||||
| 2025 | -15.51% | 10.30% | -20.79% | 24.29% | 0.77% | 6.18% | -16.80% | 9.29% | 2.05% | -12.36% | -12.13% | 15.30% | -19.11% |
| 2024 | -12.40% | -21.23% | -0.93% | -20.96% | -40.48% | -5.27% | -26.10% | -11.69% | 42.65% | -39.38% | 0.34% | 29.49% | -77.66% |
| 2023 | 154.79% | -36.45% | -27.43% | -10.08% | 12.68% | -9.50% | -3.60% | -19.76% | -39.14% | -41.50% | -2.89% | -29.34% | -79.64% |
| 2022 | 10.24% | -19.96% | -2.67% | -19.18% | 107.20% | -50.10% | -31.16% | -50.59% |
Benchmark Metrics
Heart Test Laboratories Inc. Common Stock has an annualized alpha of -7.54%, beta of 0.40, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 16, 2022.
- This stock participated in 269.25% of S&P 500 Index downside but only -81.22% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.40 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.54%
- Beta
- 0.40
- R²
- 0.00
- Upside Capture
- -81.22%
- Downside Capture
- 269.25%
Return for Risk
Risk / Return Rank
HSCS ranks 37 for risk / return — below 37% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Heart Test Laboratories Inc. Common Stock (HSCS) and compare them to a chosen benchmark (S&P 500 Index).
| HSCS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.12 | 0.90 | -1.02 |
Sortino ratioReturn per unit of downside risk | 0.48 | 1.39 | -0.91 |
Omega ratioGain probability vs. loss probability | 1.06 | 1.21 | -0.15 |
Calmar ratioReturn relative to maximum drawdown | -0.24 | 1.40 | -1.64 |
Martin ratioReturn relative to average drawdown | -0.38 | 6.61 | -6.99 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore HSCS risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Heart Test Laboratories Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Heart Test Laboratories Inc. Common Stock was 99.36%, occurring on Dec 18, 2025. The portfolio has not yet recovered.
The current Heart Test Laboratories Inc. Common Stock drawdown is 99.26%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.36% | Feb 6, 2023 | 721 | Dec 18, 2025 | — | — | — |
| -76.51% | Aug 9, 2022 | 105 | Jan 6, 2023 | 19 | Feb 3, 2023 | 124 |
| -50% | Jun 17, 2022 | 24 | Jul 22, 2022 | 8 | Aug 3, 2022 | 32 |
| -35.37% | Aug 4, 2022 | 2 | Aug 5, 2022 | 1 | Aug 8, 2022 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Heart Test Laboratories Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Heart Test Laboratories Inc. Common Stock is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HSCS relative to other companies in the Medical Devices industry. Currently, HSCS has a P/S ratio of 606.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HSCS in comparison with other companies in the Medical Devices industry. Currently, HSCS has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |